DrugPatentWatch Database Preview

Details for Patent: 8,633,309

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,633,309 protect, and when does it expire?

Patent 8,633,309 protects EPCLUSA, HARVONI, SOVALDI, and VOSEVI, and is included in six NDAs.

Protection for HARVONI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and seventy-two patent family members in thirty-seven countries.

Summary for Patent: 8,633,309

Title:	Nucleoside phosphoramidates
Abstract:	Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s):	Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Application Number:	13/738,425
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,633,309
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Recent additions to Drugs Protected by US Patent 8,633,309

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET	208341	Mar 19, 2020	RX	Yes		Y	Y			U-1470	FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET	208341	Jun 28, 2016	RX	Yes		Y	Y			U-1470	FOR THE TREATMENT OF HEPATITIS C

Drugs Protected by US Patent 8,633,309

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No			Y	Y		FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-001	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-001	Aug 28, 2019		RX	Yes	No					Y

International Family Members for US Patent 8,633,309

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3515
Argentina	080819
Argentina	080870
Argentina	081813